Načítá se...
The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors
RAF- and MEK-targeted therapies are approved for patients with BRAF(V600E) melanoma and under investigation in a several other tumor types, but resistance remains a major challenge. We uncovered yes-associated protein 1 (YAP1) as a mechanism of resistance to RAF-MEK inhibition in BRAF- and RAS-mutan...
Uloženo v:
| Vydáno v: | Mol Cell Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4845171/ https://ncbi.nlm.nih.gov/pubmed/27308535 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2015.1021441 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|